FuturHealth is stepping up the game in weight management with its new oral GLP-1 receptor agonist, Foundayo. Developed by Eli Lilly, this medication meets the increasing demand for non-injectable treatment options. Patients are looking for easier ways to control their weight and improve their health, and Foundayo delivers.
In past clinical trials, Foundayo showed its effectiveness. Obese participants lost an average of 12% of their body weight over 72 weeks while also improving their blood sugar levels. Unlike traditional injections, which many find daunting, Foundayo comes as a simple once-daily pill. This convenience makes it appealing to a broader audience looking to manage their weight more comfortably.
Dr. Michael Snyder, FuturHealth’s obesity specialist, highlights the significance of Foundayo. “What’s exciting about Foundayo is that it builds on what we already know works with GLP-1s, but without the needles. This is crucial since needles can be a major barrier for patients,” he explains.
However, it’s important to remember that medication alone won’t guarantee long-term success. According to Dr. Snyder, it should be part of a well-structured program that includes nutrition and exercise. FuturHealth has already helped over 400,000 people find sustainable solutions for their weight issues.
Luke Mahoney, co-founder and CEO, notes that the landscape for GLP-1 treatments is changing. “As medication becomes more accessible and affordable, we expect a wider demographic to engage with these therapies,” he states. The goal is not just to provide medicine but to pair it with expert guidance and ongoing support for a healthier lifestyle.
Just as significant as the introduction of new medications is the understanding of what happens after they are discontinued. Research shows that many people regain weight once they stop taking GLP-1 drugs. A study indicated that 55% of obese individuals and 45% of diabetic patients regained lost weight after ending their medication. This emphasizes the need for nutritional support during and post-treatment to maintain weight loss.
FuturHealth’s subscription-based care model offers personalized guidance to subscribers. This includes advice on nutrition, movement, and lifestyle to ensure successful weight management, both during and after medication use.
In conclusion, as treatments like Foundayo become more available, they offer hope for many seeking effective weight management solutions. However, achieving lasting results is about more than just the medication; it’s about building a lifestyle that supports long-term health.
For more insightful information on these topics, you may want to check out the Centers for Disease Control and Prevention for additional resources and data on weight management and health trends.
Source link
Eli Lilly, Oral GLP-1, FuturHealth Expansion, Foundayo
